C&R Research Inc. 2026 Profile: Korea-Based Full-Service CRO with Emerging Global Capability
An independent, sponsor-facing review of C&R Research Inc.—its South Korea CRO foundation, full-service clinical-development platform, APAC expansion, RWD/RWE direction, AI initiatives, therapeutic focus and practical fit for sponsors.
Reviewed October 2026 · Public and non-confidential information onlyHow C&R Research should be understood in 2026
C&R Research is best understood as a South Korea-based full-service CRO with a long domestic operating history, broad clinical-development capabilities, an expanding APAC network and emerging data- and technology-enabled international capability.
That positioning is stronger—and more useful to sponsors—than either extreme. C&R should not be reduced to a domestic Korean vendor, because its current public record shows overseas branches, regional partnerships, multinational trial activity and 2026 expansion across Southeast and Northeast Asia. At the same time, it should not be presented as operationally equivalent to the largest multinational CROs solely on the basis of overseas entities or partnership announcements.
Why C&R Research matters
A sponsor rarely chooses a CRO because it offers one isolated function. The practical value lies in whether clinical operations, regulatory work, medical input, data, statistics, safety and quality can be coordinated with fewer handoffs and clearer accountability.
For global sponsors entering Korea
C&R combines a long Korean operating history with local clinical operations, regulatory support and country-level execution. KoNECT lists the company as a full-service clinical CRO and records its major service priorities as Clinical Operation, Medical Writing and Regulatory Affairs.[1]
For Korean biotech expanding outward
C&R’s overseas branches and recent partnerships create a practical bridge from Korea into selected APAC markets. The value is potentially strongest where a Korean sponsor wants one coordinating CRO while retaining local-country execution.
For integrated outsourcing
Current company materials describe an end-to-end service model covering early development, trial management, regulatory affairs, data management, biostatistics, pharmacovigilance and quality management.[2]
Independent signals and company-reported scale
KoNECT—the Korean clinical-trial support organization used here as an institutional source—lists C&R Research as a Korean corporation established on 1 July 1997, with overseas branches in the United States, Thailand and Singapore. It classifies C&R as a full-service clinical CRO, records the company as a designated training institution for clinical-trial monitors, and shows K-ACRO Innovative CRO status with validity through 31 December 2026.[1]
C&R’s current website reports 500+ employees, 2,800+ clinical trials and 100+ global clinical trials.[2] KoNECT’s company profile still refers to approximately 1,800 domestic and international clinical-trial projects.[1] These totals should not be treated as a contradiction without qualification: they appear to reflect different reporting dates and potentially different counting definitions.
Service capability across the development lifecycle
C&R’s service breadth is one of the strongest parts of its public profile. The company currently presents a full-scope model spanning medical and development consulting through trial execution, data, safety, statistics and quality.[2]
Medical advisory & development strategy
Scientific and medical input can be incorporated into protocol strategy, development planning and clinical interpretation.
Early-phase clinical development
Current company materials include early-phase clinical development and first-in-human related support within the broader solution portfolio.
Trial management
Study start-up, project management, monitoring, site coordination and Phase I–III execution sit at the center of the operating model.
Regulatory affairs
Country-specific regulatory strategy, authority interactions, submissions and regulatory writing are presented as core capabilities.
Data management & biostatistics
Public materials describe eCRF and database workflows, data review, analysis, statistical outputs and submission-support activities.
Pharmacovigilance & quality
Safety management and quality functions are included as part of the end-to-end clinical-development platform.
Credibility signals—and what they do not prove
KoNECT records C&R as a training institution for clinical-trial monitors, notes the operation of C&R Academy, and lists K-ACRO Innovative CRO status through the end of 2026.[1] KoNECT also references ISO 9001 in the context of C&R Academy. That should not be generalized into a claim that every C&R clinical system or operating unit is covered by the same certification scope.
Positive public indicators
- KoNECT full-service classification
- K-ACRO Innovative CRO status
- Clinical-monitor training-institution designation
- C&R Academy and structured training infrastructure
- Publicly described SOP- and quality-system orientation
Still requires sponsor verification
- Study-specific QMS implementation
- Computerized-system validation
- Audit and inspection history
- CAPA effectiveness
- Cybersecurity and privacy controls
- Vendor and subcontractor oversight
ICH E6(R3) context for 2026
ICH E6(R3) emphasizes participant protection, reliable trial results, fit-for-purpose systems and processes, and proportionate risk management.[5] Sponsors evaluating C&R should therefore assess how its operating model implements current quality-by-design, critical-to-quality, data-governance, monitoring and vendor-oversight expectations. This profile does not infer E6(R3) compliance solely from public materials.
Where the public record shows clinical-development focus
C&R’s official therapeutic-area pages currently identify oncology, cardiovascular disease, endocrinology, dermatology, central nervous system disorders, ophthalmology and rare diseases as dedicated areas of focus.[4] The company also markets services across biotechnology, pharmaceuticals and medical devices.[2]
Oncology
Official materials describe work across solid tumors and hematologic malignancies, including protocol design, biomarker-related considerations, statistical strategy and complex oncology endpoints.[4]
Cardiovascular & endocrine
The company presents disease-specific clinical-development capability in chronic and cardiometabolic areas where long-term follow-up and complex endpoint strategies can matter.
CNS & other specialty areas
C&R lists CNS, ophthalmology, dermatology and rare diseases among its therapeutic focus areas. Sponsor assessment should still examine project-level experience for the exact indication and modality.
South Korea strength with a widening APAC network
South Korea remains C&R’s strongest and most defensible market identity. Beyond Korea, the company’s public record now shows a mix of direct branches, offices, equity relationships and CRO partnerships. These forms of presence should not be treated as equivalent, but together they support a broader APAC-facing strategy.
| Market | Publicly visible relationship | Editorial interpretation |
|---|---|---|
| South Korea | Headquarters, longest operating history, full-service KoNECT listing | Core market and strongest country-level capability |
| Singapore | Overseas branch / regional corporate presence in public materials | Useful APAC coordination signal |
| Thailand | KoNECT-listed overseas branch | Direct regional presence signal |
| Indonesia | C&R official history records an Indonesia office established in March 2026 | Recent Southeast Asia expansion; operational depth should be verified study by study |
| Vietnam | Company records a CRO partnership established in May 2026 | Partner-based expansion rather than automatically equivalent to a wholly owned branch |
| Japan | Equity stake in EPS International Korea Ltd., the Korean subsidiary of Japan’s EPS Group | Potentially important Korea–Japan / Northeast Asia connectivity; post-transaction delivery evidence is still developing |
| United States | KoNECT records a U.S. overseas branch | Supports international-facing visibility, but does not by itself establish mega-CRO global scale |
Sources: KoNECT for the U.S./Thailand/Singapore branch listing; C&R official history and current website for 2026 Indonesia, Vietnam and EPS-related developments.[1][2][3]
Why the 2025–2026 period matters
The current profile is more compelling when these developments are viewed as a sequence rather than isolated announcements. They show C&R moving from a traditional full-service Korean CRO model toward a broader regional, data and technology platform.
C&R’s official history records a global Phase II clinical-trial contract with U.S.-based Advanced Clinical.
The company acquired Mediplexus, which it identifies as an RWD/RWE healthcare-data company, adding a data-focused capability to the wider group.
C&R records the establishment of an Indonesia office, adding a direct Southeast Asia expansion signal.
The company records adoption of Taimei Technology AI agents and a Vietnam CRO partnership. These are strategic direction signals; measurable delivery impact remains less publicly documented.
C&R’s history records a U.S. confirmatory clinical trial award for a Korean digital-therapeutics program, adding a concrete international-facing milestone.
C&R reports acquiring an equity stake in EPS International Korea Ltd., the Korean subsidiary of Japan’s EPS Group, supporting a Korea–Japan / Northeast Asia strategy.
All timeline items above are based on C&R’s official history/current website and should be interpreted as company-published milestones unless independently confirmed elsewhere.[2][3]
A credible direction—without overstating operational outcomes
RWD/RWE through Mediplexus
C&R’s current website identifies Mediplexus as an RWD/RWE-based integrated healthcare data company within its network.[2] Strategically, this expands C&R’s exposure to observational research, post-marketing evidence and healthcare-data applications.
What is not yet established publicly: the scale of fully integrated multinational RWE delivery, specific datasets available to every sponsor, and comparative performance versus specialist RWE organizations.
AI and trial operations
C&R’s official history records adoption of Taimei Technology AI agents in April 2026, and the company later described continued collaboration around AI-enabled clinical research.[2][3]
What is not yet established publicly: independently measured reductions in cycle time, error rates, cost or enrollment duration. AI should therefore be treated as a capability direction, not proof of superior trial outcomes.
Who should shortlist C&R—and when another model may fit better
Strong potential fit
- Multinational sponsors conducting trials in South Korea
- Korean biotech/pharma companies expanding into multicountry development
- APAC-focused programs where Korea is a core market
- Sponsors seeking integrated operations, regulatory, data, statistics, safety and writing
- Programs that may benefit from Korea–Japan or Southeast Asia connectivity
- Post-marketing or RWD/RWE programs where C&R/Mediplexus capabilities are relevant
Another CRO model may be stronger when
- The program requires a very large directly staffed 40–50-country network
- A dedicated global central-lab platform is the dominant procurement requirement
- A highly specialized Phase I unit is more important than integrated Korea/APAC execution
- The sponsor requires deeply documented direct infrastructure in markets where C&R currently relies more on partnerships
- A niche therapeutic specialist has materially deeper indication-specific evidence
These are fit considerations, not judgments of overall CRO quality.
What should still be verified before award
A strong public profile is not a substitute for formal qualification. Before selecting C&R—or any CRO—sponsors should request study-specific evidence.
Team & therapeutic depth
- Named project leadership
- CRA availability and seniority
- Indication-specific study references
- Enrollment and site experience
Quality & systems
- SOPs and QMS
- Audit/inspection history
- Computerized-system validation
- CAPA and vendor oversight
- Cybersecurity/data privacy
Execution & commercial model
- Country-by-country staffing
- Partner/subcontractor dependencies
- Feasibility assumptions
- Governance/escalation model
- Budget and change-order terms
Where C&R Research sits in the CRO landscape
South Korea: the company has a strong case based on longevity, KoNECT full-service classification, K-ACRO status, training infrastructure, broad service coverage and domestic ecosystem relevance.
APAC: recent Indonesia, Vietnam and Japan-linked developments strengthen the regional story. The distinction between direct branches, offices, equity relationships and local CRO partners should remain transparent.
Global: C&R has credible international-facing capability and publicly reported multinational trial activity. The language should remain proportionate: emerging global-facing capability is more defensible than treating the company as directly equivalent to the largest global CRO platforms.
Frequently asked questions
What is C&R Research Inc.?
C&R Research Inc. is a South Korea-based clinical research organization established in 1997. KoNECT classifies it as a full-service clinical CRO.[1]
Is C&R Research a full-service CRO?
Yes. KoNECT lists C&R as a full-service CRO, and the company’s current website presents services spanning medical advisory, early-phase development, trial management, regulatory affairs, data management, biostatistics, pharmacovigilance and quality management.[1][2]
What are C&R Research’s main therapeutic areas?
The company’s official therapeutic pages currently identify oncology, cardiovascular disease, endocrinology, dermatology, central nervous system disorders, ophthalmology and rare diseases as dedicated areas of focus.[4]
Why is C&R relevant in APAC?
Its strongest base is South Korea, while current public materials show branches, offices, partnerships and Japan-linked investment activity extending its reach across selected Asian markets. The form and depth of presence differ by country and should be assessed individually.
What is KoNECT’s relevance to the profile?
KoNECT provides an institutional Korean CRO listing and records C&R’s full-service classification, training-institution status and K-ACRO Innovative CRO status. KoNECT information strengthens the evidence base but does not replace sponsor qualification or regulatory review.[1]
Can C&R Research be called a global CRO?
A cautious description is a Korea-based/APAC CRO with expanding international and global-facing capability. Its multinational activity is meaningful, but scale should not be equated automatically with the largest global CROs.
Primary and authoritative references
CareerAidHub prioritized institutional and first-party sources for this profile. Company claims are identified as company-reported where independent verification is not available.
- KoNECT — C&R Research CRO profile. Establishment date, full-service classification, overseas branches, training-institution designation, K-ACRO status and company summary. Open KoNECT source.
- C&R Research — Official website. Current company-reported scale, service families, network, RWD/RWE entities and current 2026 developments. Open official website.
- C&R Research — Official history. Corporate history and 2025–2026 strategic milestones including Mediplexus, Indonesia, AI agents, Vietnam, U.S. DTx and EPSI Korea. Open official history.
- C&R Research — Official therapeutic-area pages. Company-described oncology and other therapeutic-area capabilities. Open therapeutic-area source.
- ICH E6(R3) Good Clinical Practice Guideline. Current international principles for participant protection, fit-for-purpose systems, proportionate risk management and reliable trial results. Open ICH guideline.
